Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2002
04/25/2002WO2001059102A3 Nucleozymes with endonuclease activity
04/25/2002WO2001058891A3 Piperazine and piperidine derivatives for treatment or prevention of neuronal damage
04/25/2002WO2001058450A3 Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
04/25/2002WO2001056552A3 Farnesyl protein transferase inhibitors for treating breast cancer
04/25/2002WO2001052904A3 Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides
04/25/2002WO2001052830A3 METHODS TO TREAT α-1-ANTITRYPSIN DEFICIENCY
04/25/2002WO2001052651A3 Particulate blends and compacted products formed therefrom, and the preparation thereof
04/25/2002WO2001047913A3 Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect
04/25/2002WO2001047533A3 INHIBITION OF GSK-3$g(b)
04/25/2002WO2001046327A3 1,1-disubstituted ethylene adhesive compositions containing polydimethylsiloxane
04/25/2002WO2001045740A3 Compositions and methods for treatment of breast cancer
04/25/2002WO2001045687A3 Use of bioactive metabolites of gepirone for the treatment of psychological disorders
04/25/2002WO2001043753A3 Combination of ginseng and ginkgo to improve cognitive skills
04/25/2002WO2001041810A3 Nucleic acid delivery system
04/25/2002WO2001034094A3 Novel compounds to treat diabetes and associated conditions
04/25/2002WO2001028521A3 Liposome formulation of 6,9-bis-[(2-aminoethyl)-amino]benzo[g]isoquinoline-5,10-dione dimaleate
04/25/2002WO2001010431A3 Headache and colic relief composition with asafetida and method of use thereof
04/25/2002WO2001002369A3 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
04/25/2002US20020049389 Noninvasive measurement of chemical substances
04/25/2002US20020049345 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
04/25/2002US20020049344 New vitamin d derivatives with carbo-or heterocyclic substituents at c-25, a process for their production, intermediate products and their use for producing medicaments
04/25/2002US20020049335 DNA alkylating compounds such as 1-(tert-butyloxycarbonyl) -4-hydroxy-3(((methane-sulfonyl)oxy)methyl)-2,3-dihydroindole
04/25/2002US20020049329 Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them
04/25/2002US20020049328 Such as (R)-1-Cyclopropyl-8-difluoromethoxy-7-(1-methyl-2,3-dihydro-1H-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxyl ic acid methanesulfonate; chemical intermediates; bactericides; catalysis
04/25/2002US20020049327 Such as 7-(3-chlorophenyl)-9-((4-chlorophenyl)-1H-imidazol-1-ylmethyl)-2,3-dihydro -1H,5H-benzo(ij)quinolizin-5-one; for forming oncogenes for signalling transformation of tumor cells
04/25/2002US20020049326 Benzosulfones and related compositions and methods
04/25/2002US20020049325 Calcium channel blockers
04/25/2002US20020049324 Topoisomerase inhibitors
04/25/2002US20020049322 Quinoline and quinazoline compounds useful in therapy
04/25/2002US20020049313 Method for introducing foreign material into higher eukaryotic cells
04/25/2002US20020049299 Oxidizing and polymerizing aromatic compounds of at least one hydroxyl and carbonyl groups or at least two hydroxyl groups; humic acids
04/25/2002US20020049281 Contacting with crosslinking agents so as to form two or more chemically distinct crosslinks between hyaluronic acid and the polymer; products with medical applications
04/25/2002US20020049257 Possibly methoxylated norbornanyl-cyclohexanols; acne treatment; deodorant
04/25/2002US20020049256 Anti- neoplastic, anti-diarrheal, anti-peristaltic, gastro-intestinal anti-spasmodic, anti-viral, anti-retroviral, anti-psoriasis and insecticidal compositions
04/25/2002US20020049255 Method of treating neurodegenerative disorders of the retina and optic nerve head
04/25/2002US20020049254 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease
04/25/2002US20020049253 Structural or functional components of the creatine kinase/ phosphocreatine system sufficient to prevent, reduce or ameliorate skin damage or skin aging
04/25/2002US20020049252 Methods, compositions and modes of delivery for the treatment of emphysema using 13-cis-retinoic acid
04/25/2002US20020049251 Wedelolactone and its synthesis for treating neurodegenerative diseases
04/25/2002US20020049250 PPAR receptor activator compounds for treating cutaneous disorders/afflictions
04/25/2002US20020049249 PPAR receptor activator compounds for treating cutaneous disorders/afflictions
04/25/2002US20020049248 Alone or in combination for treatment of adult-T-cell leukemia- lymphoma
04/25/2002US20020049245 Tumor necrosis factor alpha (TNF-alpha) inhibiting pharmaceuticals
04/25/2002US20020049244 Treatment of disease or disease symptoms mediated by eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE) a potent constrictor of renal, cerebral and skeletal muscle arterioles
04/25/2002US20020049243 Pyrrolidine derivatives
04/25/2002US20020049240 Novel compounds
04/25/2002US20020049239 Novel indole and benzothiazole derivatives
04/25/2002US20020049238 Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
04/25/2002US20020049237 Statin-MMP inhibitor combinations
04/25/2002US20020049236 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
04/25/2002US20020049234 Inhibitors of factor Xa; for example 3-(4-tert-butylbenzoyl)amino-N-(4-methoxyphenyl)-2-thiophenecarboxamide
04/25/2002US20020049233 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor
04/25/2002US20020049232 Method of treating parkinson's disease
04/25/2002US20020049231 S(-)-3-aminothalidomide; treating wide variety of diseases including diabetic retinopathy
04/25/2002US20020049230 Administering reboxetine and derivatives to treat drug abuse, drug dependence, alcoholism, and tobacco/nicotine addiction, as well as Attention Deficit Hyperactivity Disorder (ADHD)
04/25/2002US20020049226 Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis
04/25/2002US20020049225 Quinuclidine-substituted aryl compounds for treatment of disease
04/25/2002US20020049224 Alpha v integrin receptor antagonists
04/25/2002US20020049222 Cyclopentyl modulators of chemokine receptor activity
04/25/2002US20020049221 Analogs of deoxypreussomerin, palmarumycin CPI and related naphthoquinone spiroketals; inhibit thioredoxin-thioredoxin reductase system
04/25/2002US20020049220 Substituted azoles
04/25/2002US20020049218 2-, 6, and 9-substituted purine derivatives, particularly 2(1-R hydroxymethylpropylamino)-6-benzylamino-9-isopropyl purine, used as drug and herbicide; inhibiting effect with respect to cyclin-dependent kinase proteins
04/25/2002US20020049215 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
04/25/2002US20020049214 Aralkyl and aralkylidene heterocyclic lactams and imides as selective agonists and antagonists of serotonin 1 (5-HT1) recepor, used in treating hypertension and all forms of depression
04/25/2002US20020049212 Benzimidazole compounds and salts containing piperidine ring are useful in treatment or prevention or medical conditions selected from pain, and inflammatoy diseases; analgesics
04/25/2002US20020049211 Combination treatment for depression and anxiety
04/25/2002US20020049210 Heteroaryl amines as novel acetylcholinesterase inhibitors
04/25/2002US20020049209 Dopamine D4 ligands for the treatment of novelty-seeking disorders
04/25/2002US20020049208 Imidazo[1,2-a]pyrazines for the treatment of neurological disorders
04/25/2002US20020049207 Nitrogen containing heterobicyclic compounds for treating disorders manifesting hypersecretion of corticotropin releasign factor(CRF) in a warm-blooded animals, such as stroke
04/25/2002US20020049206 Compounds for the treatment of addictive disorders
04/25/2002US20020049205 Pyrazole antimicrobial agents
04/25/2002US20020049204 1,4-dihydro-benzo(d)oxazin-2-one derivatives useful for treating hormone-dependent neoplastic disease is selected from uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy, carcinomas, and adenocarcinoma
04/25/2002US20020049203 CRF receptor antagonists and methods relating thereto
04/25/2002US20020049202 Administering halogenated amidino or oxyamidino compound to treat diseases caused by nitric oxide synthase
04/25/2002US20020049200 Use of a methylol-containing compound to treat tumors
04/25/2002US20020049199 N-linked carbamates and ureas of heterocyclic thioesters
04/25/2002US20020049198 Administering to a patient having or at risk of having osteoarthritis, a therapeutically effective amount of an bicyclicaromatic or heteroaromatic compound containing amine and hydroxy groups
04/25/2002US20020049197 Aminoquinazolines and their use as medicaments
04/25/2002US20020049196 Hexahydro-pyrazolo-(4,3-c)pyridine derivatives useful for increasing the endogenous production or release of growth hormone in a human or other animal, thus treat or prevent osteoporosis
04/25/2002US20020049195 Urea compounds that are muscarinic receptor antagonists and agonists, administering to the mammal the urea compound to treat urinary incontinence, chronic pulmonary obstructive disease, asthma, hyper salivation, blurred vision etc.
04/25/2002US20020049194 A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist
04/25/2002US20020049193 Inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.
04/25/2002US20020049190 Useful in binding nitric oxide; inhibiting tumor growth
04/25/2002US20020049189 Vanadium (IV) complexes containing catecholate ligand and having spermicidal activity
04/25/2002US20020049188 Relieving pain associated with anal fissures.
04/25/2002US20020049186 Phenylazophenylacetic acid derivatives; treating inflammatory bowel disease
04/25/2002US20020049185 Malonic acid based matrix metalloproteinase inhibitors
04/25/2002US20020049183 Phospholipids, espeically phosphatidylethanolamines, covalently bound to physiologically acceptable monomers or polymers.
04/25/2002US20020049182 Administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies.
04/25/2002US20020049180 KIAA0175 inhibitor is selected from the group consisting of an anti-sense molecule, a ribozyme, an antibody, an antibody fragment, a protein, a polypeptide and a small molecule.
04/25/2002US20020049177 Detecting an aberrant level or bioactivity of or screening for a Wnt pathway component or a frizzled related protein gene product
04/25/2002US20020049174 First region is available for hybridization and the second region is temporarily masked.
04/25/2002US20020049172 Chlamydia oligosaccharides
04/25/2002US20020049171 Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
04/25/2002US20020049170 Method for reducing toxicity of combined chemotherapies
04/25/2002US20020049169 Administration of 7-methylthiomethyl taxol and doxorubicin
04/25/2002US20020049167 Azithromycin as a therapeutic agent for infections with leishmania parasites
04/25/2002US20020049166 Antineoplastic agents and antioxidants; preservative and topiosomerase-inhibiting compositions
04/25/2002US20020049161 Especially Fe(III) saccharate and gluconate; treatment of hemodialysis patients.